MX2022004779A - Agonistas del receptor del péptido 1 similar al glucagón (glp-1) en demencia. - Google Patents

Agonistas del receptor del péptido 1 similar al glucagón (glp-1) en demencia.

Info

Publication number
MX2022004779A
MX2022004779A MX2022004779A MX2022004779A MX2022004779A MX 2022004779 A MX2022004779 A MX 2022004779A MX 2022004779 A MX2022004779 A MX 2022004779A MX 2022004779 A MX2022004779 A MX 2022004779A MX 2022004779 A MX2022004779 A MX 2022004779A
Authority
MX
Mexico
Prior art keywords
glp
receptor agonists
dementia
semaglutide
subjects
Prior art date
Application number
MX2022004779A
Other languages
English (en)
Spanish (es)
Inventor
Sarah Friedrich
Charlotte Christine Thim Hansen
Lotte Bjerre Knudsen
Anna Secher
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73172681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022004779(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2022004779A publication Critical patent/MX2022004779A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022004779A 2019-11-06 2020-11-05 Agonistas del receptor del péptido 1 similar al glucagón (glp-1) en demencia. MX2022004779A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19207501 2019-11-06
EP20186623 2020-07-20
PCT/EP2020/081087 WO2021089678A1 (en) 2019-11-06 2020-11-05 Glp-1 receptor agonists in dementia

Publications (1)

Publication Number Publication Date
MX2022004779A true MX2022004779A (es) 2022-06-14

Family

ID=73172681

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004779A MX2022004779A (es) 2019-11-06 2020-11-05 Agonistas del receptor del péptido 1 similar al glucagón (glp-1) en demencia.

Country Status (19)

Country Link
US (4) US20220280612A1 (https=)
EP (2) EP4414031A3 (https=)
JP (2) JP7670698B2 (https=)
KR (1) KR20220110731A (https=)
CN (1) CN114728042A (https=)
AU (1) AU2020377469A1 (https=)
BR (1) BR112022007721A2 (https=)
CA (1) CA3154744A1 (https=)
ES (1) ES2984177T3 (https=)
HR (1) HRP20241052T1 (https=)
HU (1) HUE067514T2 (https=)
IL (1) IL291876A (https=)
MA (1) MA57599B1 (https=)
MX (1) MX2022004779A (https=)
PH (1) PH12022550842A1 (https=)
PL (1) PL4054620T3 (https=)
RS (1) RS65780B1 (https=)
TW (1) TWI890704B (https=)
WO (1) WO2021089678A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL291876A (en) 2019-11-06 2022-06-01 Novo Nordisk As Receptor agonists in glp-1 type dementia
KR20220132606A (ko) * 2020-01-30 2022-09-30 일라이 릴리 앤드 캄파니 둘라글루티드의 치료 용도
US20240050531A1 (en) * 2020-12-16 2024-02-15 The Chinese University Of Hong Kong A method for reversing aging brain functional decline
KR20240123816A (ko) 2021-12-02 2024-08-14 쾨벤하운스 유니버시테트 퇴행성 신경 질환의 치료를 위한 펩티드-약물 접합체
WO2024179606A1 (zh) * 2023-03-02 2024-09-06 甘李药业股份有限公司 一种glp-1化合物的医药用途
CN120131965A (zh) * 2025-04-10 2025-06-13 瓯江实验室 Glp-1受体激动剂治疗阿尔茨海默病的用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
AU3357800A (en) 1999-02-05 2000-08-25 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
WO2001092206A1 (en) 2000-06-02 2001-12-06 Emisphere Technologies, Inc. Method of preparing salicylamides
ATE408414T1 (de) 2001-07-31 2008-10-15 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CN101258163B (zh) 2005-06-30 2013-08-21 益普生制药股份有限公司 Glp-1药物组合物
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
US8501693B2 (en) 2006-08-04 2013-08-06 Amylin Pharmaceuticals, Llc Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
BRPI0716539A2 (pt) 2006-09-07 2016-11-01 Emisphere Tech Inc métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
SI2651398T1 (en) * 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
EP2866825B1 (en) * 2012-07-01 2020-04-08 Novo Nordisk A/S Use of long-acting glp-1 peptides
ES2741507T3 (es) 2014-04-07 2020-02-11 Novo Nordisk As Compuestos de glp-1 acilados doblemente
WO2016198624A1 (en) * 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
US20170112897A1 (en) * 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
CN108697768B (zh) 2015-12-23 2022-07-22 约翰霍普金斯大学 长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法
US20190142905A1 (en) 2016-04-19 2019-05-16 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
IL291876A (en) 2019-11-06 2022-06-01 Novo Nordisk As Receptor agonists in glp-1 type dementia
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤

Also Published As

Publication number Publication date
US20230302094A1 (en) 2023-09-28
HRP20241052T1 (hr) 2024-11-08
EP4054620A1 (en) 2022-09-14
EP4414031A3 (en) 2025-02-05
EP4054620C0 (en) 2024-05-29
CA3154744A1 (en) 2021-05-14
HUE067514T2 (hu) 2024-10-28
EP4414031A2 (en) 2024-08-14
JP2023500032A (ja) 2023-01-04
RS65780B1 (sr) 2024-08-30
WO2021089678A1 (en) 2021-05-14
MA57599B1 (fr) 2024-06-28
CN114728042A (zh) 2022-07-08
TW202519256A (zh) 2025-05-16
US12539326B2 (en) 2026-02-03
KR20220110731A (ko) 2022-08-09
ES2984177T3 (es) 2024-10-29
US20220280612A1 (en) 2022-09-08
TW202118509A (zh) 2021-05-16
AU2020377469A1 (en) 2022-04-28
JP7670698B2 (ja) 2025-04-30
EP4054620B1 (en) 2024-05-29
JP2025027130A (ja) 2025-02-26
IL291876A (en) 2022-06-01
TWI890704B (zh) 2025-07-21
US20250099549A1 (en) 2025-03-27
US20240207364A1 (en) 2024-06-27
PL4054620T3 (pl) 2024-10-14
PH12022550842A1 (en) 2023-10-09
BR112022007721A2 (pt) 2022-07-12

Similar Documents

Publication Publication Date Title
PH12022550842A1 (en) Glp-1 receptor agonists in dementia
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
MX2016013244A (es) Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
PH12019501010A1 (en) Arginase inhibitor combination therapies
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
MX2021005382A (es) Vehiculos derivados de cholix para suministro oral de carga util heterologa.
MX2018000362A (es) Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon.
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
MY191321A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
GB201201314D0 (en) Composition
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
ZA201700196B (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
PH12021551540A1 (en) Anti-il-36r antibodies for treatment of palmoplantar pustulosis
ECSP20000655A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
HK1263322A1 (zh) 使用长双歧杆菌调节情绪反应性并治疗或预防亚临床心境紊乱的方法和组合物
PH12017501290A1 (en) Treatment of pediatric type 2 diabetes mellitus patients with lixisenatide
WO2020009740A3 (en) Compositions and methods of use thereof for treatment of metabolic diseases and related disorders
MX2018010096A (es) Tratamiento de pacientes con hipercolesterolemia familiar homocigota en terapia de disminucion de lipidos.
MX2023011202A (es) Agonistas de receptores alfa de ácido retinoico (rara) para el tratamiento de leucemia mieloide aguda (aml) y síndrome mielodisplásico (mds).
CL2025003984A1 (es) Semaglutida en terapia médica.